In this episode, HBW Insight talks probiotics with David Pineda Ereño, founder of DPE International Consulting and consultant to the International Probiotics Association. Since 2006, no health claims for probiotics have been allowed by harmonized European Union regulations. Even the term "probiotic" is considered an unauthorized health claim by the European Commission. However, as Pineda Ereño explains, many EU member states, including Italy and Spain, are starting to go their own way, adopting a more liberal approach to this booming wellness market. We discuss what the future of EU probiotics regulation may hold, as well as some recent exciting scientific developments, pointing to the health benefits of these extremely popular products.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”
AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.
Just under half of Austrian pharmacists surveyed by Elpato Medien are “convinced that the OTC business will ensure the survival of their pharmacy.”
HBW Insight catches up with UK OTC industry association CEO Michelle Riddalls to talk about digital self-care and the unrealized promise of Brexit - part 2.
An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.
HBW Insight catches up with UK OTC industry association CEO Michelle Riddalls to talk about digital self-care and the unrealized promise of Brexit - part 2.
Engaging with EU member state legislators, stressing the impact of national EPR systems on the accessibility, availability, and affordability of medicines, reformulating products to reduce their financial contribution, and lobbying for expanding the scope of EPR schemes to include other polluting industries are all ways that the European consumer health industry can try and influence the way that the revised Urban Wastewater Treatment Directive is transposed into national legislation, law firm Mason Hayes & Curran explains.
